Published in Nucl Med Biol on January 01, 2007
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A (2011) 1.16
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des (2008) 1.00
Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol (2011) 0.96
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. EJNMMI Res (2015) 0.88
Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release (2010) 0.82
A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline. Ann Nucl Med (2013) 0.80
Total Radiosynthesis: Thinking outside "the box". Aust J Chem (2015) 0.77
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol (2010) 0.77
Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. PLoS One (2016) 0.75
Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol (2014) 0.75
Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA. Biomed Res Int (2013) 0.75
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med (2006) 3.51
ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep (2002) 2.61
Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol (2006) 1.81
Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem (2006) 1.70
18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med (2007) 1.61
Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med (2004) 1.51
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol Ther (2004) 1.50
Cisplatin-induced activation of the EGF receptor. Oncogene (2002) 1.48
Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem (2002) 1.42
Blood vessels restrain pancreas branching, differentiation and growth. Development (2011) 1.35
Information-theoretic analysis of phenotype changes in early stages of carcinogenesis. Proc Natl Acad Sci U S A (2010) 1.24
Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS One (2009) 1.24
On a fundamental structure of gene networks in living cells. Proc Natl Acad Sci U S A (2012) 1.21
IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol (2006) 1.19
A perfusion-independent role of blood vessels in determining branching stereotypy of lung airways. Development (2011) 1.18
EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med (2005) 1.15
Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. BMC Syst Biol (2011) 1.13
Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol (2005) 1.12
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett (2003) 1.11
Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes. J Biol Chem (2009) 1.11
Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot (2010) 1.09
Localization of parathyroid adenoma by ¹¹C-choline PET/CT: preliminary results. Clin Nucl Med (2014) 1.08
Growth-limiting role of endothelial cells in endoderm development. Dev Biol (2011) 1.08
Killing time for cancer cells. Nat Rev Cancer (2005) 1.08
Molecular imaging of chemokine receptor CXCR4. Theranostics (2013) 1.04
Anomalous features of EMT during keratinocyte transformation. PLoS One (2008) 1.03
Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry (2002) 1.03
Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells. PLoS One (2007) 1.02
Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol (2009) 1.02
Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat Biotechnol (2002) 1.01
Reducing health disparities: strategy planning and implementation in Israel's largest health care organization. Health Serv Res (2011) 0.99
The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J Infect Dis (2002) 0.99
Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Mol Imaging Biol (2012) 0.96
Chelator-free (64)Cu-integrated gold nanomaterials for positron emission tomography imaging guided photothermal cancer therapy. ACS Nano (2014) 0.96
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther (2002) 0.96
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res (2002) 0.94
Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol (2004) 0.92
EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res (2010) 0.92
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal (2011) 0.92
Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem (2003) 0.92
Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation. J Biol Chem (2011) 0.92
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Intrinsically radioactive [64Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence. ACS Nano (2015) 0.90
PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life (2012) 0.90
CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics (2013) 0.89
Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials (2005) 0.88
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem (2003) 0.87
In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med (2005) 0.87
Targeted cancer therapy: promise and reality. Adv Cancer Res (2007) 0.87
Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl Med Biol (2004) 0.87
Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem (2004) 0.86
One-pot two-step radiosynthesis of a new (18)F-labeled thiol reactive prosthetic group and its conjugate for insulinoma imaging. Mol Pharm (2014) 0.85
The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. Appl Radiat Isot (2007) 0.85
A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry (2007) 0.85
Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res (2010) 0.85
Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer (2002) 0.85
A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Mol Ther (2005) 0.84
Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids (2011) 0.84
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res (2004) 0.83
11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med (2012) 0.83
Gating, enhanced gating, and beyond: information utilization strategies for motion management, applied to preclinical PET. EJNMMI Res (2013) 0.83
Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human Papilloma virus 16. PLoS One (2007) 0.82
64Cu-labeled lissamine rhodamine B: a promising PET radiotracer targeting tumor mitochondria. Mol Pharm (2011) 0.82
Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril (2006) 0.82
Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem (2005) 0.82
Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions. Bioorg Med Chem (2010) 0.82
RNA molecules as anti-cancer agents. Semin Cancer Biol (2004) 0.82
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J Med Chem (2011) 0.82
Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. Appl Radiat Isot (2003) 0.81
Tumor specific activation of PKR as a non-toxic modality of cancer treatment. Semin Cancer Biol (2003) 0.81
Expression and purification of active PKB kinase from Escherichia coli. Protein Expr Purif (2005) 0.81
Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units. J Pept Sci (2010) 0.81
A color discriminating broad range cell staining technology for early detection of cell transformation. J Carcinog (2009) 0.81
Targeted cancer immunotherapy. Curr Opin Pharmacol (2013) 0.81
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett (2006) 0.81
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorg Med Chem (2011) 0.80
Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means. PLoS One (2013) 0.80
Contribution of gross chromosomal changes to HPV16-induced transformation. Mol Biosyst (2011) 0.80
Feeling vigorous and the risks of all-cause mortality, ischemic heart disease, and diabetes: a 20-year follow-up of healthy employees. Psychosom Med (2010) 0.79
Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release (2012) 0.79
Evaluation of 64Cu-labeled acridinium cation: a PET radiotracer targeting tumor mitochondria. Bioconjug Chem (2011) 0.79
ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol (2007) 0.79
Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med (2012) 0.78
Structure--activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET--myocardial perfusion imaging agents. Mol Imaging Biol (2012) 0.78
Work-based predictors of mortality: a 20-year follow-up of healthy employees. Health Psychol (2011) 0.78
Subunit S5a of the 26S proteasome is regulated by antiapoptotic signals. FEBS J (2007) 0.78
PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Mol Imaging Biol (2015) 0.78